Andrew Bellinger - Jul 13, 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role: CSO & CMO
Signature: /s/ Andrew Ashe, as Attorney-in-Fact for Andrew Bellinger
Stock symbol: VERV
Transactions as of: Jul 13, 2022
Transactions value $: -$234,200
Form type: 4
Date filed: 7/15/2022, 05:00 PM
Previous filing: Feb 15, 2022
Next filing: Jul 22, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VERV	Common Stock	Options Exercise	$14.8K	+10K	+150.85%	$1.48^*	16.6K	Jul 13, 2022	Direct	F1
transaction	VERV	Common Stock	Sale	-$249K	-10K	-60.14%	$24.90	6.63K	Jul 13, 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VERV	Stock Option (right to buy)	Options Exercise	$0	-10K	-6.8%	$0.00	137K	Jul 13, 2022	Common Stock	10K	$1.48	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,629 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.
F2	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2022.
F3	The remaining shares underlying this option, which was granted on September 17, 2019 and commenced vesting on October 1, 2019, vest in equal monthly installments until October 1, 2023.